The global antibiotics active pharmaceutical ingredient (API) market is projected to witness steady growth over the next decade. Valued at USD 8,653.0 million in 2023, the market is expected to expand at a CAGR of 3.3%, reaching a projected valuation of USD 12,002.3 million by 2033.
The rising demand for antibiotics, driven by the increasing prevalence of bacterial infections and the growing need for advanced therapeutic solutions, is contributing to this market growth. Key players in the industry are focused on enhancing their production capabilities and investing in research and development to meet the rising global demand for antibiotics APIs.
This growth is driven by the increasing demand for antibiotics in the treatment of bacterial infections, rising awareness of antimicrobial resistance, and ongoing advancements in pharmaceutical manufacturing technologies. The expansion of healthcare infrastructure and the development of novel antibiotics to combat resistant strains are also contributing to the market’s positive outlook.
The antibiotics API market plays a crucial role in the global healthcare ecosystem by providing essential components for the production of life-saving medications. As the demand for effective and innovative antibiotics continues to rise, the market is positioned for sustained growth and advancement.
Additionally, increased healthcare expenditure by governments is enabling greater funding for antibiotic drug development and manufacturing. This is sustainably fueling the upward growth trajectory of the Global Antibiotics Active Pharmaceutical Ingredient Industry.
The COVID-19 pandemic is anticipated to have a detrimental effect on the market for antibiotic APIs. Several of the biggest pharmaceutical companies, research universities, and biotech companies have been chosen to address the issue. They are now focusing on creating coronavirus vaccines rather than other drugs as a result. Hospital beds are scarce, and several APIs are in short supply.
Due to the rising demand and widespread use of penicillin as a first-line antibiotic therapy to treat various bacterial infections, the penicillin antibiotics segment dominated the antibiotics API market in 2021 with a market share of 51.1%. It is anticipated that pharmaceutical corporations will dominate the end-user market. Through the projected period, they are anticipated to hold more than 77% of the market and continue to dominate.
Key Takeaways from Global Antibiotics Active Pharmaceutical Ingredient Industry Study
- The Global Antibiotics Active Pharmaceutical Ingredient Industry is estimated to be US$ 8.01 Bn in 2020, with the market expected to exhibit a CAGR of 3.1% during the forecast period (2020-2030)
- The U.S. holds over 92.1% share of the North American market, but Canada is projected to expand faster CAGR
- The U.K. market will showcase steady y-o-y growth at 2.1% in 2021
- The demand from Germany and France will rise at a positive rate through the forecast period
- Within East Asia China will emerge as a key market, while Japan and South Korea will continue exhibiting steady demand
“Increasing prevalence of bacterial diseases, extreme use of antibiotics and rising investment in R&D are expected to boost the growth of the Global Antibiotics Active Pharmaceutical Ingredient Industry.” says the FMI Analyst
Rising investment in R&D sector in order to develop advanced molecules is the major factor expected to boost the antibiotic API market growth.
For instance, Sandoz, the Novartis biosimilars and generics division, undergoes a joint investment, with the Austrian federal government, to enhance the long-term future of integrated antibiotics manufacturing in Europe.
Key players in the Global Antibiotics Active Pharmaceutical Ingredient Industry are Entering into the Strategic Alliance
The top players are focusing on increasing acquisitions at regional levels. Acquisitions empower the company with products and increase the company’s portfolio. The company acquires to possess well-established products and solutions that expects to account good revenue source for the acquirer. This also enables the company to enter new emerging markets as well as enhance the existing markets.
For instance, in August 2019, Nanjing Dorra Pharmaceutical Technology collaborated with Meitheal Pharmaceuticals, the fully integrated generic injectables company, for elevating the manufacturing capacity of the active pharmaceutical ingredients in the region of U.S. The collaboration enabled Meitheal Pharmaceuticals to invest into the Nanjing Dorra Pharmaceutical Technology.
Who is Winning?
The Global Antibiotics Active Pharmaceutical Ingredient Industry is set to expand its scope in the forecast period, as a result of rising prevalence of various bacterial diseases, and growing investment in R&D. The antibiotics market is highly competitive and consists of several major players. Pharmaceutical companies are more focused towards outsourcing of antibiotics API manufacturing due to the involvement of high capital investment in the establishment of Antibiotics API manufacturing units.
The key market players covered by FMI include:
Sandoz International GmbH, Centrient Pharmaceuticals, CordenPharma International, ACS DOBFAR SPA, Nanjing Dorra Pharmaceutical Technology Co. Ltd., DAEWOONG PHARMACEUTICAL CO. LTD., Parabolic Drugs Ltd., Penam Laboratories Ltd., ASIATIC DRUGS & PHARMACEUTICALS PVT. LTD., Fresenius Kabi, The United Laboratories International Holdings Limited, Aurobindo Pharma Limited, Unimark Remedies Ltd., Savior Lifetec, Shenzhen Haibin Pharmaceutical Co., Ltd., Sterile India Pvt. Ltd., Zhejiang Jiuzhou Pharmaceutical Co. Ltd., and Kyongbo Pharm, consolidating their positions through mergers, acquisitions and new product launches.
A Old Full Report Analysis Click Here
Key segments profiled in the antibiotics active pharmaceutical ingredient (API) market Industry survey
By API Type:
- Penicillin Antibiotics
- Ampicillin
- Amoxicillin
- Dicloxacillin
- Penicillin G Sodium
- Benzathine
- Procaine
- Cephalosporins
- Cefotaxime
- Ceftriaxone
- Cefuroxime
- Cefalotin
- Carbapenem Antibiotics
- Meropenem
- Imipenem
- Ertapenem
By End User:
- Pharmaceutical Companies
- Contract Manufacturing Organizations (CMOs)
- Contract Development & Manufacturing Organizations (CDMOs)
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Middle East and Africa (MEA)
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
